<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Supp/5-HTP.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:33:52 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="2793000">
<meta name="Category" content="Supp">
<meta name="Article" content="5-HTP">
<title>5-Hidroxitriptofano-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">5-Hidroxitriptofano</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="5-HTP.htm">Volver al art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Guyton AC, Hall JE. <em>Textbook of Medical Physiology</em>, 9th ed.
Philadelphia: W. B. Saunders, 1996.</li>

<li class="Ref">van Praag HM, Lemus C. Monoamine precursors in the treatment of psychiatric
disorders. <em>Nutrition and the Brain,</em> vol. 7, eds. RJ Wurtman, JJ Wurtman. New York:
Raven Press, 1986 [review].</li>

<li class="Ref">Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3H-imipramine uptake
receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome.
<em>J Rheumatol</em> 1992;19:90&#8211;4.</li>

<li class="Ref">Yunus MB, Dailey JW, Aldag JC, et al. Platelet 3H-imiprimine uptake receptor
density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. <em>J
Rheumatol</em> 1992;19:104&#8211;9.</li>

<li class="Ref">Wolfe F, Russell IJ, Vipraio G, et al. Serotonin levels, pain threshold, and
fibromyalgia symptoms in the general population. <em>J Rheumatol</em>
1997;24:555&#8211;9.</li>

<li class="Ref">Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients.
<em>Neurology</em> 1960;10:107&#8211;11.</li>

<li class="Ref">Schneider-Helmert D, Spinweber CL. Evaluation of L-tryptophan for treatment of
insomnia: A review. <em>Psychopharmacology</em> (Berlin) 1986;89(1):1&#8211;7.</li>

<li class="Ref">Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of
5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. <em>J
Int Med Res</em> 1990;18:201&#8211;9.</li>

<li class="Ref">Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-hydroxytryptophan: A review of
its antidepressant efficacy and adverse effects . <em>J Clin Psychopharmacol</em>
1987;7:127&#8211;37 [review].</li>

<li class="Ref">Zmilacher K, Battegay R, Gastpar M. L-5-hydroxytryptophan alone and in
combination with a peripheral decarboxylase inhibitor in the treatment of depression. <em>
Neuropsychobiology</em> 1988;20:28&#8211;35.</li>

<li class="Ref">Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to
depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan
and fluvoxamine. <em>Psychopathology</em> 1991;24(2):53&#8211;81.</li>

<li class="Ref">Soulairac A, Lambinet H. Etudes cliniques de l&#237;action du precurseur de la
serotonine le L-5-hydroxy-tryptophane, sur les troubles du sommeil. <em>Schweiz Bundschau Med
(PRAXIS)</em> 1998;77(34a):19&#8211;23 [in French].</li>

<li class="Ref">De Benedittis G, Massei R. 5-HT precursors in migraine prophylaxis: a
double-blind cross-over study with L-5-hydroxytryptophan versus placebo. <em>Clin J Pain</em>
1986;3:123&#8211;9.</li>

<li class="Ref">Titus F, Davalos A, Alom J, Codina A. 5-hydroxytryptophan versus methysergide
in the prophylaxis of migraine. <em>Eur Neurol</em> 1986;25:327&#8211;9.</li>

<li class="Ref">Maissen CP, Ludin HP. Comparison of the effect of 5-hydroxytryptophan and
propranolol in the interval treatment of migraine. <em>Schweizerische Medizinische
Wochenschrift /Journal Suisse de Medecine</em> 1991;121:1585&#8211;90 [in German].</li>

<li class="Ref">Mathew NT. 5-hydroxytryptophan in the prophylaxis of migraine. <em>
Headache</em> 1978;18:111&#8211;3.</li>

<li class="Ref">De Giorgis G, Miletto R, Iannuccelli M, et al. Headache in association with
sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study
&#241; L-5-HTP versus placebo. <em>Drugs Exptl Clin Res</em> 1987;13(7):425&#8211;33.</li>

<li class="Ref">Ribeiro CA. L-5-Hydroxytryptophan in the prophylaxis of chronic tension-type
headache: a double-blind, randomized, placebo-controlled study. <em>Headache</em>
2000;40:451&#8211;6.</li>

<li class="Ref">Ceci F, Cangiano C, Cairella M, et al. The effects of oral 5-hydroxytryptophan
administration on feeding behavior in obese adult female subjects.<em>J Neural Transm</em>
1989;76(2):109&#8211;17.</li>

<li class="Ref">Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary
prescriptions in obese adult subjects treated with 5-hydroxytryptophan. <em>Am J Clin
Nutr</em> 1992;56:863&#8211;7.</li>

<li class="Ref">Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan
on energy intake and macronutrient selection in non-insulin dependent diabetic patients. <em>
Int J Obes Relat Metab Disord</em> 1998;22:648&#8211;54.</li>

<li class="Ref">Williamson BL, Benson LM, Tomlinson AJ, et al. On-line HPLC-tandem mass
spectrometry analysis of contaminants of L-tryptophan associated with the onset of the
eosinophilia-myalgia syndrome. <em>Toxicol Lett</em> 1997;92:139&#8211;48.</li>

<li class="Ref">Williamson BL, Klarskov K, Tomlinson AJ, et al. Problems with over-the-counter
5-hydroxy-L-tryptophan. <em>Nat Med</em> 1998;4:983.</li>

<li class="Ref">Williamson BL, Tomlinson AJ, Mishra PK, et al. Structural characterization of
contaminants found in commercial preparations of melatonin: similarities to case-related
compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. <em>Chem Res
Toxicol</em> 1998;11:234&#8211;40.</li>

<li class="Ref">Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of
the eosinophilia-myalgia syndrome associated with tryptophan use<em>. N Engl J Med</em>
1990;323:357&#8211;65.</li>

<li class="Ref">Martin RW, Duffy J, Engel AG, et al. The clinical spectrum of the
eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20
patients and aspects of pathophysiology<em>. Ann Intern Med</em> 1990;113:124&#8211;34.</li>

<li class="Ref">Mayeno AN, Lin F, Foote CS, et al. Characterization of &#8220;peak E,&#8221; a
novel amino acid associated with eosinophilia-myalgia syndrome. <em>Science</em>
1990;250:1707&#8211;8.</li>

<li class="Ref">Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of
the eosinophilia-myalgia syndrome associated with tryptophan use<em>. N Engl J Med</em>
1990;323:357&#8211;65.</li>

<li class="Ref">Mayeno AN, Lin F, Foote CS, et al. Characterization of &#8220;peak E,&#8221; a
novel amino acid associated with eosinophilia-myalgia syndrome. <em>Science</em>
1990;250:1707&#8211;8.</li>

<li class="Ref">Reinauer S, Plewig G. [Eosinophilia-myalgia syndrome]. <em>Hautarzt</em>
1991;42(3):137&#8211;9 [in German].</li>

<li class="Ref">Toyo&#8217;oka T, Yamazaki T, Tanimoto T, et al. Characterization of
contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography.
<em>Chem Pharm Bull (Tokyo)</em> 1991;39(3):820&#8211;2.</li>

<li class="Ref">Trucksess MW, Thomas FS, Page SW. High-performance liquid chromatographic
determination of 1,1&#8217;-ethylidenebis(L-tryptophan) in L-tryptophan preparations<em>. J
Pharm Sci</em> 1994;83(5):720&#8211;2.</li>

<li class="Ref">Trucksess MW. Separation and isolation of trace impurities in L-tryptophan by
high-performance liquid chromatography<em>. J Chromatogr</em>
1993;630(1&#8211;2):147&#8211;50.</li>

<li class="Ref">Ito J, Hosaki Y, Torigoe Y, Sakimoto K. Identification of substances formed by
decomposition of peak E substance in tryptophan<em>. Food Chem Toxicol</em>
1992;30(1):71&#8211;81.</li>

<li class="Ref">Castot A, Bidault I, Bournerias I, et al. [&#8220;Eosinophilia-myalgia&#8221;
syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional
Centers of Pharmacovigilance. Analysis of 24 cases]. <em>Therapie</em> 1991;46(5):355&#8211;65
[in French].</li>

<li class="Ref">Michelson D, Page SW, Casey R, et al. An eosinophilia-myalgia syndrome related
disorder associated with exposure to L-5-hydroxytryptophan. <em>J Rheumatol</em>
1994;21:2261&#8211;5.</li>

<li class="Ref">Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like
illness during therapy with L-5-hydroxytryptophan and carbidopa. <em>N Engl J Med</em>
1980;303(14):782&#8211;7.</li>

<li class="Ref">Johnson KL, Klarskov K, Benson LM, et al. Presence of peak X and related
compounds: the reported contaminant in case related 5-Hydroxy-L-tryptophan associated with
eosinophilia-myalgia syndrome. <em>J Rheumatol</em> 1999;26(12):2714&#8211;7.</li>

<li class="Ref">Hagan JJ, Hatcher JP, Slade PD. The role of 5-HT1D and 5-HT1A receptors in
mediating 5-hydroxytryptophan induced myoclonic jerks in guinea pigs. <em>Eur J Pharmacol</em>
1995;294:743&#8211;51.</li>

<li class="Ref">Green AR, Johnson P, Mountford JA, Nimgaonkar VL. Some anticonvulsant drugs
alter monoamine mediated behaviour in mice in ways similar to electroconvulsive shock;
implications for antidepressant therapy. <em>Br J Pharmacol</em> 1985;84:337&#8211;46.</li>

<li class="Ref">Bourin M, Hascoet M, Deguiral P. 5-HTP induced diarrhea as a carcinoid
syndrome model in mice? <em>Fundam Clin Pharmacol</em> 1996;10:450&#8211;7.</li>

<li class="Ref">Hirai M, Nakajima T. Biochemical studies on the mechanism of difference in the
renal toxicity of 5-hydroxy-L-tryptophan between Sprague Dawley and Wistar rats. <em>J Biochem
(Tokyo)</em> 1979;86:907&#8211;13.</li>

<li class="Ref">Martin TG. Serotonin syndrome. <em>Ann Emerg Med</em>
1996;28:520&#8211;6.</li>

<li class="Ref">Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like
illness during therapy with L-5-hydroxytryptophan and carbidopa. <em>N Engl J Med</em>
1980;303:782&#8211;7.</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Supp/5-HTP.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:33:52 GMT -->
</html>

